Condition: Biliary Tract Carcinoma
Interventions: Drug: Pembrolizumab; Drug: Gemcitabine; Drug: Cisplatin; Drug: Placebo
Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting
Feeds
32378 items (32378 unread) in 74 feeds
Acinar Cell Carcinoma
(227 unread)
Acinic Cell Carcinoma
(127 unread)
Adenoid Cystic Carcinoma
(705 unread)
Adrenal Gland Cancer
(2666 unread)
Ampulla Of Vater
(958 unread)
Anal Cancer
(3342 unread)
Angiosarcoma
(1002 unread)
Appendix Cancer
(438 unread)
Bile Duct Cancer
(3816 unread)
Brain and CNS
(4383 unread)
Carcinoid
(1375 unread)
Endocrine/Neuroendocrine
(3718 unread)
Gall Bladder Cancer
(1447 unread)
Hemangioendothelioma
(317 unread)
Hepatoblastoma
(515 unread)
Pancreas
(425 unread)
Phyllodes
(259 unread)
PMP and Mucinous Tumors
(314 unread)
Rhabdomyosarcoma
(1171 unread)
Sarcoma
(5173 unread)
Trials - Gall Bladder Cancer (27 unread)
-
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Posted: July 1st, 2019, 2:00pm GMT
-
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Posted: June 27th, 2019, 2:00pm GMT
Conditions: Peripheral T Cell Lymphoma; Diffuse Large B Cell Lymphoma; Biliary Tract Cancer; Extranodal NK T Cell Lymphoma, Nasal
Intervention: Biological: STI-3031
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting -
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
Posted: June 13th, 2019, 2:00pm GMT
Conditions: Tumor, Solid; Gall Bladder Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Pancreatic Cancer; Clear Cell Renal Cell Carcinoma
Intervention: Drug: Andes-1537 for Injection
Sponsor: Andes Biotechnologies
Recruiting -
Bile Composition in Healthy and Gallstones Patients
Posted: June 10th, 2019, 2:00pm GMT
Conditions: Cholelithiasis; Gall Stone; Gall Bladder Disease
Interventions: Diagnostic Test: Bile test; Diagnostic Test: Blood test; Diagnostic Test: Gall stone study; Diagnostic Test: Microbiological bile test
Sponsor: Hospital Son Espases
Not yet recruiting -
Fluorescence Imaging in Hepatobiliary Surgery
Posted: May 13th, 2019, 2:00pm GMT
Condition: Hepatobiliary Surgery
Interventions: Drug: Indocyanine Green; Device: Cancer goggle system
Sponsor: Washington University School of Medicine
Not yet recruiting -
Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer
Posted: May 6th, 2019, 2:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Biological: 'SMT-NK' Inj (allogeneic Natural Killer cell); Drug: Pembrolizumab Injection [Keytruda]
Sponsor: SMT bio Co., Ltd.
Not yet recruiting -
Analysis of the Impact of Cholecystectomy on Gut Microbiome in Adults
Posted: February 11th, 2019, 3:00pm GMT
Condition: Laparoscopic Cholecystectomy
Intervention: Procedure: Laparoscopic cholecystectomy
Sponsor: Shanghai Jiao Tong University School of Medicine
Recruiting -
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
Posted: February 7th, 2019, 3:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Intervention: Drug: M7824
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting -
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Posted: January 11th, 2019, 3:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Biliary Tract Neoplasms
Intervention: Biological: Tumor Infiltrating Lymphocytes (TIL)
Sponsor: Udai Kammula
Recruiting -
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
Posted: December 7th, 2018, 3:00pm GMT
Conditions: Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Drug: Nab-paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting -
Multicenter Prospective Cohort Study of Risk Factors for Gallbladder Cancer
Posted: December 4th, 2018, 3:00pm GMT
Conditions: Gallbladder Diseases; Healthy
Intervention: Other: Benigh gallbladder diseases
Sponsor: Tongji Hospital
Not yet recruiting -
Primary EUS-GBD in Patients With Unresectable Malignant Biliary Obstruction and Cystic Duct Orifice Involvement.
Posted: November 5th, 2018, 3:00pm GMT
Condition: Acute Cholecystitis
Interventions: Procedure: EUS-guided gallbladder drainage; Procedure: Non EUS-guided gallbladder drainage
Sponsor: Instituto Ecuatoriano de Enfermedades Digestivas
Recruiting -
Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer
Posted: October 24th, 2018, 2:00pm GMT
Conditions: Pancreatic Cancer; Resectable Pancreatic Cancer
Interventions: Drug: Pimonidazole; Procedure: Surgical Resection
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Varian Medical Systems
Not yet recruiting -
Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer
Posted: July 9th, 2018, 2:00pm GMT
Conditions: Stage I Gallbladder Cancer AJCC v8; Stage II Gallbladder Cancer AJCC v8; Stage IIA Gallbladder Cancer AJCC v8; Stage IIB Gallbladder Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8
Interventions: Drug: Capecitabine; Drug: Cisplatin; Drug: Gemcitabine
Sponsor: Emory University
Recruiting -
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
Posted: August 22nd, 2017, 2:00pm GMT
Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma; Unresectable Pancreatic Carcinoma
Interventions: Biological: Durvalumab; Drug: Guadecitabine
Sponsors: University of Southern California; National Cancer Institute (NCI); Van Andel Research Institute
Recruiting -
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
Posted: April 28th, 2017, 2:00pm GMT
Conditions: Radiation Therapy; Cancer; Cancer of Anus; Cancer of Bladder; Cancer of Cervix; Cancer of Colon; Cancer of Rectum; Cancer of Esophagus; Cancer of Gallbladder; Cancer of Liver; Cancer of Ovary; Cancer of Pancreas; Cancer of Prostate; Cancer of Kidney and Renal Pelvis; Cancer of Stomach; Cancer of Testis; Cancer of Uterus; Cancer of Uterus and Cervix; Cancer of Kidney
Intervention:
Sponsors: DxTerity Diagnostics; National Cancer Institute (NCI)
Recruiting -
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Posted: April 13th, 2017, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Cholangiocarcinoma; Bile Duct Cancer; Liver Cancer; Gallbladder Cancer
Interventions: Biological: Pembrolizumab (MK-3475); Drug: Oxaliplatin; Drug: Capecitabine
Sponsor: National Cancer Institute (NCI)
Recruiting -
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
Posted: February 6th, 2017, 3:00pm GMT
Conditions: Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic; Cholangiocarcinoma of the Gallbladder; Cholangiocarcinoma Advanced
Interventions: Drug: nal-IRI; Drug: 5-FU; Drug: leucovorin
Sponsors: AIO-Studien-gGmbH; SERVIER (Shire)
Recruiting -
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Posted: October 5th, 2016, 2:00pm GMT
Conditions: Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm
Interventions: Drug: Ipilimumab; Drug: Nivolumab
Sponsors: Olivia Newton-John Cancer Research Institute; Bristol-Myers Squibb
Recruiting -
Hepatic Resection for Metastatic Pancreatic Cancer
Posted: September 8th, 2016, 2:00pm GMT
Conditions: Pancreatic Neoplasms; Neoplasm Metastasis; Liver Metastases
Intervention: Procedure: Hepatic Resection or Ablation with Pancreaticoduodenectomy
Sponsor: Duke University
Recruiting -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Posted: July 15th, 2016, 2:00pm GMT
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction
Posted: January 20th, 2016, 3:00pm GMT
Conditions: Cholangiocarcinoma; Gallbladder Cancer; Pancreatic Cancer; HCC; AOV Cancer
Interventions: Procedure: side by side; Procedure: stent in stent
Sponsor: Yonsei University
Recruiting -
Efficacy and Safety of Endobiliary Radiofrequency Ablation by Using a Novel RF Catheter (ELRA®) on Maintaining the Patency of Endobiliary Metal Drainage in Patients With Malignant Biliary Strictures : A Double-arm Comparable Study
Posted: January 5th, 2016, 3:00pm GMT
Condition: Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer
Interventions: Device: Radiofrequency ablation with stenting; Device: stenting
Sponsor: Yonsei University
Recruiting -
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Posted: December 16th, 2015, 3:00pm GMT
Conditions: Biliary Carcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma; Gastrointestinal Tumor
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Copanlisib
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Bayer
Recruiting -
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
Posted: August 11th, 2015, 2:00pm GMT
Conditions: Cholangiocarcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Stage III Gallbladder Cancer AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Biological: Ramucirumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
Posted: January 29th, 2015, 3:00pm GMT
Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer; Uterine Cancer; Mesotheliomas; Gastrointestinal Cancers; Cervical Cancer
Interventions: Device: HIPEC: MMC 30mg @ T0, 10mg @ T45min; Device: HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0; Device: HIPEC: CDDP 75 mg/m2 @T0; Device: HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
Sponsor: Bay Area Gynecology Oncology
Recruiting -
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
Posted: June 23rd, 2014, 2:00pm GMT
Conditions: Cholangiocarcinoma; Gall Bladder Carcinoma
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Capecitabine
Sponsors: Universitätsklinikum Hamburg-Eppendorf; Deutsche Krebshilfe e.V., Bonn (Germany); medac GmbH; Cancer Research UK; Australasian Gastro-Intestinal Trials Group; Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG)
Recruiting